Summary Metastatic spread of some solid tumours is thought to depend upon the adhesion of tumour cells to the vascular endothelium followed by extravasation into surrounding tissues. We investigated the role of ,B1 integrins in the adhesion of the breast adenocarcinoma cell line MDA-MB-231 and the melanoma cell line RPMI-7951 to quiescent human umbilical vein endothelial cells (HUVEC) (Honn and Tang, 1992) . These transmembrane glycoproteins are composed of two non-covalently associated subunits termed a and fi. There are at least 14 a-subunits (150-200 kDa) and eight P-subunits (90-210 kDa). The cxsubunits can associate with more than one type of f-unit, leading to a wide range of integrin dimers (Hynes, 1992; Albelda and Buck, 1990) . Ligand binding is dependent upon divalent cations (Gailit and Ruoslahti, 1988) . The ligand recognised by integrins depends upon the particular cc-and ,Bsubunits within the complex, and requires both subunits (Buck et al., 1986) . Endothelial integrins are involved in adhesion to extracellular matrix (ECM) molecules and in maintaining the integrity of the monolayer. Endothelial cells express f,l, f3 and fl5 chains. The #1 integrins, which are expressed on a wide range of cell types, dimerise with acs 1-6 and thereby mediate cellular adhesion to laminin, collagen and fibronectin (Dejana, 1993) . Integrins are also expressed on a variety of tumour cells, and changes in their expression may play a role in malignant progression and metastasis (Albelda, 1993; Juliano and Varner, 1993) .
The interaction of tumour cells with endothelial cells lining the microvasculature is an important step in the metastatic cascade. A variety of endothelial and tumour adhesion molecules have been implicated in this process, and much attention has focused on the role of the integrin family of receptors (Honn and Tang, 1992) . These transmembrane glycoproteins are composed of two non-covalently associated subunits termed a and fi. There are at least 14 a-subunits (150-200 kDa) and eight P-subunits . The cxsubunits can associate with more than one type of f-unit, leading to a wide range of integrin dimers (Hynes, 1992; Albelda and Buck, 1990) . Ligand binding is dependent upon divalent cations (Gailit and Ruoslahti, 1988) . The ligand recognised by integrins depends upon the particular cc-and ,Bsubunits within the complex, and requires both subunits (Buck et al., 1986) . Endothelial integrins are involved in adhesion to extracellular matrix (ECM) molecules and in maintaining the integrity of the monolayer. Endothelial cells express f,l, f3 and fl5 chains. The #1 integrins, which are expressed on a wide range of cell types, dimerise with acs 1-6 and thereby mediate cellular adhesion to laminin, collagen and fibronectin (Dejana, 1993) . Integrins are also expressed on a variety of tumour cells, and changes in their expression may play a role in malignant progression and metastasis (Albelda, 1993; Juliano and Varner, 1993) .
In addition to mediating adhesion to extracellular matrix components, beta-l integrins have also been reported to play a role in tumour cell-endothelial cell adhesion. Lauri et al. (1991) Silver staining of HUVEC HUVECs were grown to confluence in 24-well dishes precoated with rat tail tendon collagen, which was allowed to gel (Boehringer Mannheim, Germany). Gels were formed according to the manufacturer's instructions. Adhesion assays (1984) .
Results
FACScan analysis demonstrated high levels of cell surface expression of ,B1 integrins on both tumour cell lines ( Figure  1 ). However, only the RPMI-7951 line expressed the a4,B1 integrin VLA-4, which is the ligand for VCAM-1 on activated endothelial cells (Rice and Bevilacqua, 1989) .
Immunofluorescence staining of intact HUVEC monolayers confirmed the expression of,1 integrins by endothelial cells; staining was particularly intense at endothelial cell -cell junctions (Figure 2 ). We previously demonstrated that both MDA-MB-231 and RPMI-7951 tumour cells adhere to monolayers of quiescent HUVEC in preference to gelatin, in the absence of cytokine activation (Price et al., 1995) . Under these conditions, differential adhesion to HUVEC was maximal after 30 min, when 40%+3% (n= 12) of MDA-MB-231 and 47%+2% (n = 12) of RPMI-7951 tumour cells are adherent to HUVEC monolayers. Consequently, all measurements were made after 30 min of incubation and adhesion data are hereafter expressed as per cent control adhesion at 30 min.
We observed that blocking of cell-surface /1 integrins, by preincubation of either HUVECs or tumour cells with anti-CD29 (MAb 13), caused significant reductions in adhesion (Figure 3) . When both HUVECs and tumour cells were pretreated simultaneously with antibody, the overall reduction in adhesion obtained was approximately equal to the sum of the separate changes. Although RPMI-7951 cells express the ,B1 integrin VLA-4 (see Figure 1) _-* Discussion Beta-I integrins are expressed at high levels on the surface of both the MDA-MB-231 and the RPMI-7951 cell lines. In addition, we found that these integrins are expressed by HUVEC, on which they tend to be concentrated at cell -cell junctions, as shown by Lampugnani et al. (1991) . We also observed that the tumour cells tend to localise at such sites during adhesion assays. Beta-I integrins on both cell types appear to function as adhesion molecules in our model, as blocking these integrins on either the tumour cells or HUVECs led to significant reductions in adhesion. This adhesion is not based upon a homotypic interaction, as simultaneous blocking of integrins on both tumour cell lines and HUVECs produced an additive effect, which suggests a heterotypic interaction between these cells. Beta-I integrin expression on endothelial cells has previously been demonstrated (Lampugnani et al., 1991) . They are also expressed on normal breast epithelium, on their neoplastic counterparts at reduced levels (Mechtersheimer et al., 1993) , and on melanoma cells (Elices and Hemmler, 1989) . Recently Maemura et al. (1995) , while studying a2#1 expression using a range of normal and malignantly transformed breast epithelial cell lines, showed that this integrin is universally expressed but that its function as a receptor for laminin is altered in a manner which appears to be correlated with metastatic potential. Therefore, while highly metastatic breast cell lines such as the MDA-MB-231 line (used in this study) express this integrin, its affinity for laminin is reduced. This suggests that not tumour cell a2fll but rather some other /1 integrin may be involved in adhesion to endothelial cells in our model. Alternatively, a ligand other than laminin on the endothelium is involved.
Many integrins are capable of interacting with multiple ligands (Hynes, 1992) ; indeed, the ligand recognised by an integrin may depend upon which cell type it is expressed on (Elices and Hemler, 1989) . Nor is there any reason to assume that while /1 integrins on both tumour and endothelial cells are involved in adhesion they interact with the same ligands on either cell. As stated earlier, f1 integrins mediate the adhesion of cells to extracellular matrix proteins; the integrin a5fl1, for example, mediates adhesion to fibronectin.
However, MDA-MB-23 1 cells shed much of their newly synthesised fibronectin into the culture medium (Incardona et al., 1993) , discounting fibronectin as the tumour ligand for endothelial integrins. Lauri et al. (1991) found that endothelial fibronectin was not involved in the ,B1 integrinmediated adhesion of various tumour cell lines to HUVEC. Other extracellular matrix molecules such as epiligrin (Carter et al., 1991) and collagen (Wayner and Carter, 1987) Another potential ligand for the /1 integrins, expressed on both tumour and endothelial cells, is thrombospondin (TSP) (Bornstein, 1995) . MDA-MB-231 cells synthesise TSP and express high-affinity TSP receptors (Incardona et al., 1993) ; our preliminary data show that the RPMI-7951 cell line also expresses TSP (data not shown). Additionally, HUVEC express both TSP receptors and TSP clusters on the apical surface, which mediate the adhesion of MCF-7 breast adenocarcinoma cells (Incardona et al., 1995) .
We may surmise that the unidentified endothelial ligand, like the ,B1 integrins, must be expressed predominantly at intercellular junctions. The transmembrane glycoprotein CD31 (PECAM-1), which is highly enriched in endothelial junctions, may play a role. CD31 participates in heterophilic interactions with proteoglycans (Muller et al., 1992) , and it has been postulated to play a role in tumour cell adhesion and migration through blood vessel walls (Honn and Tang, 1992; Tang et al., 1993) . CD31 does not interact in a ligand/ counterligand manner with P1 integrins; however CD3 1 expressed on T-cell subsets has been shown to act as a preferential amplifier of ,B1 integrin-mediated adhesion to endothelial cells (Tanaka et al., 1992) . This suggests that the presence of CD31 at the endothelial cell -cell junction would tend to favour integrin-based interactions, preferentially amplifying the activity of /31 integrins at this site.
We conclude that ,B1 integrins expressed at endothelial cell-cell junctions and on the surface of the MDA-MB-231 and RPMI-795 1 tumour cell lines mediate heterotypic adhesion. The ligands remain obscure. Putting these observations into a physiological context, the model suggests that such interactions localise tumour cells to sites where they may more readily initiate the process of extravasation from the vasculature through the blood vessel wall and into the extravascular space. Furthermore, such a mechanism is more physiologically relevant in that it is dependent upon constitutively expressed molecules and not upon prior 'activation' of endothelial cells.
